|Title:||Therapeutic development based on the immunopathogenic mechanisms of psoriasis||Authors:||Tseng, Jen Chih
Chang, Yung Chi
Huang, Chun Ming
Chuang, Tsung Hsien
|Keywords:||Anti-psoriasis drugs | Autoimmune | Skin inflammation | Therapeutic antibody | Toll-like receptor||Issue Date:||1-Jul-2021||Publisher:||MDPI||Journal Volume:||13||Journal Issue:||7||Source:||Pharmaceutics||Abstract:||
Psoriasis, a complex inflammatory autoimmune skin disorder that affects 2–3% of the global population, is thought to be genetically predetermined and induced by environmental and immunological factors. In the past decades, basic and clinical studies have significantly expanded knowledge on the molecular, cellular, and immunological mechanisms underlying the pathogenesis of psoriasis. Based on these pathogenic mechanisms, the current disease model emphasizes the role of aberrant Th1 and Th17 responses. Th1 and Th17 immune responses are regulated by a complex network of different cytokines, including TNF-α, IL-17, and IL-23; signal transduction pathways downstream to the cytokine receptors; and various activated transcription factors, including NF-κB, interferon regulatory factors (IRFs), and signal transducer and activator of transcriptions (STATs). The biologics developed to specifically target the cytokines have achieved a better efficacy and safety for the systemic management of psoriasis compared with traditional treatments. Nevertheless, the current therapeutics can only alleviate the symptoms; there is still no cure for psoriasis. Therefore, the development of more effective, safe, and affordable therapeutics for psoriasis is important. In this review, we discussed the current trend of therapeutic development for psoriasis based on the recent discoveries in the immune modulation of the inflammatory response in psoriasis.
|Appears in Collections:||分子醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.